PharmaDiplomacy

The PharmaDiplomacy Dialogue began in late 2013 as an initiative of senior health systems and industry personnel who share a common desire to tackle the challenge of mistrust between the pharmaceutical industry and its key stakeholders.  The group came together to address the opportunity to improve relations between these groups in order to achieve the shared goals of improved patient outcomes, health system productivity, disease management, and affordable medicine expenditure.

It became clear early in the PharmaDiplomacy discussions that rebuilding inter-personal trust was a necessary but insufficient pre-condition in order to address the trust deficit between industry and health systems personnel. It therefore explored the possibility of using diplomatic approaches to getting things done.

The project developed a methodology built on these diplomatic tools to help the group find common cause and to navigate their differences by adopting transparent and predictable processes. The central focus of the project became drug pricing. This was for two reasons. First, drug pricing today is a huge source of mistrust   and is leading to high levels of antagonism. The second, related point is that if a diplomatic approach can work on such a controversial issue, it would hold lessons for other difficult issues

The PharmaDiplomacy Principles

To support healthcare participants to come to agreement on the value of medicines, which is reflected in price, the PharmaDiplomacy group has  developed  a set of Principles .

The set of Principles is designed to:

  • Provide more targeted and better outcomes for patients and providers
  • Address payer concerns about affordability and budget impact by providing greater certainty and control on price, data and volume
  • Support and encourage innovation within the drug industry

The PharmaDiplomacy Guidelines underwent a period of consultation with US and European stakeholders between September and December 2015.

The findings from the consultation will be incorporated into the final PharmaDiplomacy report, which will be launched in May 2016, followed by a process of dissemination.

Who is involved?

The dialogue is led by forward-looking senior executives in industry and health systems, willing to engage in open and constructive challenge, and to commit to actions that could accelerate trust and collaboration. This includes leaders from industry, health system payers, providers and HTAs from Europe and US, government advisors, and patient organisations. These leaders frame the trust agenda; provide leadership and support to initiatives and take lessons into other fora.

Below is the core group involved in the project:

James Anderson, Head of Corporate Government Affairs, GlaxoSmithKline
Richard Ashcroft, Professor of Bioethics, Queen Mary University of London
Marc Boutin, Chief Executive Officer, National Health Council
Tanisha Carino, Vice President, U.S. Public Policy, GlaxoSmithKline
David Cavan, Director of Policy & Programmes, International Diabetes Federation
William Crown, Chief Scientific Officer, Optum Labs
Charlotte Ersbøll, Corporate Vice President, Global Stakeholder Engagement, Novo Nordisk
Richard Evans, Founder & Managing Director, Sector Sovereign
Thomas Graf, Chief Medical Officer, Geisinger Health System (April 2004 – Aug 2015)
Jane Griffiths, Company Group Chairman, Janssen Pharmaceuticals, EMEA, Johnson & Johnson
David Haslam, Chairman, UK National Institute for Health and Care Excellence (NICE)
Nick Hicks, Chief Executive, COBIC
Niels Lund, Corporate Vice President, Global Stakeholder Engagement. Novo Nordisk
Peter Neumann, Director of the Center for the Evaluation of Value and Risk in Health, Tufts University School of Medicinen
Jacob Messina, Healthcare Analyst, RobecoSAM
Jamey Millar, Senior Vice President, Managed Markets & Government Affairs, GlaxoSmithKline
Blasine Penkowski, Vice President, Customer Strategy, Strategic Customer Group, Johnson & Johnson
Thomas Pogge, Leitner Professor of Philosophy and International Affairs, Yale University
Roger Ray, Executive Vice President and Chief Medical Officer, Carolinas HealthCare System
Ri de Ridder, Director General, Belgian National Institute for Health and Disability Insurance
(RIZIV-INAMI)
Lewis Sandy, SVP for Clinical Advancement, United Healthcare
Ad Schuurman, Vice-President, The Medicine Evaluation Committee (MEDEV)
Mark Skinner, President/ Chief Executive Officer, Institute for Policy Advancement
Chris Strutt, Senior Vice President, Government Affairs, Public Policy and Patient
Advocacy, GlaxoSmithKline
Sean Tunis, President and Chief Executive Officer, Center for Medical Technology Policy
Stijn Vanacker, Global Healthcare Analyst, Robeco
Robert Weil, Chief Medical Executive, Geisinger Northeast, Geisinger Health System

Related Resources

Pathways to Value: Pharma in a Changing World
Interview with Sophia Tickell on the key conclusions of the latest PharmaFutures dialogue

For further information on PharmaDiplomacy, please contact:info@meteos.co.uk